Anna Radominska-Pandya

List of Publications by Year in Descending Order

94 papers	4,194 citations	36 h-index	64 g-index
94 ext. papers	4,429 ext. citations	3.8 avg, IF	4.85 L-index

#	Paper	IF	Citations
94	Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development. *Life Sciences*, **2021**, 285, 119993	6.8	0
93	Significance of Competing Metabolic Pathways for 5F-APINACA Based on Quantitative Kinetics. *Molecules*, **2020**, 25,	4.8	1
92	Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity. *Pharmacology Biochemistry and Behavior*, **2020**, 195, 172949	3.9	7
91	Identifying cytochrome P450s involved in oxidative metabolism of synthetic cannabinoid N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135). *Pharmacology Research and Perspectives*, **2020**, 8, e00561	3.1	1
90	Enzymatic analysis of glucuronidation of synthetic cannabinoid 1-naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22). *Xenobiotica*, **2019**, 49, 1388-1395	2	1
89	Convulsant Effects of Abused Synthetic Cannabinoids JWH-018 and 5F-AB-PINACA Are Mediated by Agonist Actions at CB1 Receptors in Mice. *Journal of Pharmacology and Experimental Therapeutics*, **2019**, 368, 146-156	4.7	12
88	Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants. *Biochemical and Biophysical Research Communications*, **2018**, 498, 597-602	3.4	19
87	Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to Δ9-THC. *Frontiers in Pharmacology*, **2018**, 9, 1084	5.6	14
86	Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development. *PLoS ONE*, **2016**, 11, e0167240	3.7	10
85	Human UDP-Glucuronosyltransferases: Effects of altered expression in breast and pancreatic cancer cell lines. *Cancer Biology and Therapy*, **2015**, 16, 714-23	4.6	15
84	Antitumor 1-nitroacridine, C-1748, Decreases Pro-survival Autophagy and Induces Accumulation of Lipid Droplets Resulting in Apoptosis of Panc-1 Pancreatic Cancer Cells. *FASEB Journal*, **2015**, 29, 715.8	0.9	
83	Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?. *Life Sciences*, **2014**, 97, 45-54	6.8	202
82	Single-walled carbon nanotube and graphene nanodelivery of gambogic acid increases its cytotoxicity in breast and pancreatic cancer cells. *Journal of Applied Toxicology*, **2014**, 34, 1188-99	4.1	42
81	Novel resveratrol-based substrates for human hepatic, renal, and intestinal UDP-glucuronosyltransferases. *Chemical Research in Toxicology*, **2014**, 27, 536-45	4	9
80	A potential role for human UDP-glucuronosyltransferase 1A4 promoter single nucleotide polymorphisms in the pharmacogenomics of tamoxifen and its derivatives. *Drug Metabolism and Disposition*, **2014**, 42, 1392-400	4	9
79	Functional consequences of synthetic cannabinoid metabolites and CYP2C9 polymorphisms (838.4). *FASEB Journal*, **2014**, 28, 838.4	0.9	
78	K2 toxicity: fatal case of psychiatric complications following AM2201 exposure. *Journal of Forensic Sciences*, **2013**, 58, 1676-80	1.8	74

77	Targeted metabolomic approach for assessing human synthetic cannabinoid exposure and pharmacology. *Analytical Chemistry*, **2013**, 85, 9390-9	7.8	27
76	Forensic investigation of K2, Spice, and "bath salt" commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. *Forensic Science International*, **2013**, 233, 416-22	2.6	77
75	Metabolic transformation of antitumor acridinone C-1305 but not C-1311 via selective cellular expression of UGT1A10 increases cytotoxic response: implications for clinical use. *Drug Metabolism and Disposition*, **2013**, 41, 414-21	4	11
74	CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen. *Biochemical and Biophysical Research Communications*, **2013**, 441, 339-43	3.4	19
73	Sulfaphenazole and naphthoflavone attenuate the metabolism of the synthetic cannabinoids JWH-018 and AM2201 found in K2/spice. *Drug Metabolism Letters*, **2013**, 7, 34-8	2.1	11
72	Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. *Biochemical Pharmacology*, **2012**, 83, 952-61	6	131
71	Role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10. *Drug Metabolism and Disposition*, **2012**, 40, 1736-43	4	18
70	Natural prenylated resveratrol analogs arachidin-1 and -3 demonstrate improved glucuronidation profiles and have affinity for cannabinoid receptors. *Xenobiotica*, **2012**, 42, 139-56	2	34
69	Analysis of R- and S-hydroxywarfarin glucuronidation catalyzed by human liver microsomes and recombinant UDP-glucuronosyltransferases. *Journal of Pharmacology and Experimental Therapeutics*, **2012**, 340, 46-55	4.7	14
68	Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. *Drug Metabolism and Disposition*, **2012**, 40, 2174-84	4	156
67	A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors. *Chemical Research in Toxicology*, **2012**, 25, 825-7	4	49
66	Glucuronides of antitumor agents C-1311 and C-1305 modulate cytotoxicity in cancer cells. *FASEB Journal*, **2012**, 26, 966.2	0.9	
65	Functionalized-single-walled nanotube (f-SWNT)-assisted in vitro delivery of the oncogene suppressor genes to cancer cells. *FASEB Journal*, **2012**, 26, 580.8	0.9	
64	Phenylalanine 93 of the human UGT1A10 plays a major role in the interactions of the enzyme with estrogens. *Steroids*, **2011**, 76, 1465-73	2.8	10
63	Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases. *Drug Metabolism and Disposition*, **2011**, 39, 1967-76	4	67
62	Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. *Analytical Chemistry*, **2011**, 83, 4228-36	7.8	133
61	Ethylenediamine functionalized-single-walled nanotube (f-SWNT)-assisted in vitro delivery of the oncogene suppressor p53 gene to breast cancer MCF-7 cells. *International Journal of Nanomedicine*, **2011**, 6, 1045-55	7.3	42
60	Solid-phase extraction and quantitative measurement of omega and omega-1 metabolites of JWH-018 and JWH-073 in human urine. *Analytical Chemistry*, **2011**, 83, 6381-8	7.8	86

59	Flavin monooxygenases, FMO1 and FMO3, not cytochrome P450 isoenzymes, contribute to metabolism of anti-tumour triazoloacridinone, C-1305, in liver microsomes and HepG2 cells. *Xenobiotica*, **2011**, 41, 1044-55	2	15
58	Preface. *Drug Metabolism Reviews*, **2010**, 42, 1-2	7	3
57	The crystal structure of human UDP-glucuronosyltransferase 2B7 C-terminal end is the first mammalian UGT target to be revealed: the significance for human UGTs from both the 1A and 2B families. *Drug Metabolism Reviews*, **2010**, 42, 133-44	7	60
56	Targeted nanoparticle delivery of tumor suppressing UDP-glucuronosyltransferase (UGT) genes into cancer cells. *FASEB Journal*, **2010**, 24, 520.5	0.9	
55	Dopamine is a low-affinity and high-specificity substrate for the human UDP-glucuronosyltransferase 1A10. *Drug Metabolism and Disposition*, **2009**, 37, 768-75	4	47
54	Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. *Drug Metabolism and Disposition*, **2009**, 37, 1496-504	4	102
53	Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. *Chemical Research in Toxicology*, **2009**, 22, 1239-45	4	35
52	Comparative characterization of UDP-glucuronic acid (UDP-GlcUA) binding-site directed inhibitors with human UGT2B7 and 1A10.. *FASEB Journal*, **2009**, 23, 750.4	0.9	
51	The glucuronidation of native and oxidized estrogens can be effectively inhibited by compounds structurally related to UDP-glucuronic acid in human recombinant UGT1A10. *FASEB Journal*, **2009**, 23, 750.2	0.9	1
50	Characterization of mutation in the 395DQxD398 motif of the glucuronic acid binding site in human UGT1A6: Comparison to UGT1A10. *FASEB Journal*, **2009**, 23, 750.5	0.9	
49	Novel identification of UDP-glucuronosyltransferase 1A10 as an estrogen-regulated target gene. *Steroids*, **2008**, 73, 139-47	2.8	18
48	Identification of UDP-glucuronosyltransferase 1A10 in non-malignant and malignant human breast tissues. *Steroids*, **2008**, 73, 611-20	2.8	31
47	Identification of hydroxywarfarin binding site in human UDP glucuronosyltransferase 1a10: phenylalanine90 is crucial for the glucuronidation of 6- and 7-hydroxywarfarin but not 8-hydroxywarfarin. *Drug Metabolism and Disposition*, **2008**, 36, 2211-8	4	11
46	Effect of retinoids on UDP-glucuronosyltransferase 2B7 mRNA expression in Caco-2 cells. *Drug Metabolism and Pharmacokinetics*, **2008**, 23, 364-72	2.2	14
45	The first aspartic acid of the DQxD motif for human UDP-glucuronosyltransferase 1A10 interacts with UDP-glucuronic acid during catalysis. *Drug Metabolism and Disposition*, **2008**, 36, 517-22	4	12
44	Glucuronidation of monohydroxylated warfarin metabolites by human liver microsomes and human recombinant UDP-glucuronosyltransferases. *Journal of Pharmacology and Experimental Therapeutics*, **2008**, 324, 139-48	4.7	36
43	Human hepatic and extrahepatic UDP-glucuronosyltransferase (UGTs) enzymes involved in the metabolism of cannabinoids. *FASEB Journal*, **2008**, 22, 711.4	0.9	
42	Human UGT1A8 and UGT1A10 mRNA are expressed in primary human hepatocytes. *Drug Metabolism and Pharmacokinetics*, **2007**, 22, 152-61	2.2	13

41	Phenylalanine(90) and phenylalanine(93) are crucial amino acids within the estrogen binding site of the human UDP-glucuronosyltransferase 1A10. *Steroids*, **2007**, 72, 85-94	2.8	29
40	CYP2E1 active site residues in substrate recognition sequence 5 identified by photoaffinity labeling and homology modeling. *Archives of Biochemistry and Biophysics*, **2007**, 459, 59-69	4.1	22
39	Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7. *Journal of Molecular Biology*, **2007**, 369, 498-511	6.5	146
38	Aspartic Acid393 of the DxxD Motif within The C-Terminal Region of Human UDP-Glucuronosyltransferase 1A10 is Critical to the Binding of UDP-Glucuronic Acid. *FASEB Journal*, **2007**, 21, A1187	0.9	
37	Resveratrol is efficiently glucuronidated by UDP-glucuronosyltransferases in the human gastrointestinal tract and in Caco-2 cells. *Biopharmaceutics and Drug Disposition*, **2006**, 27, 181-9	1.7	55
36	Phenylalanine 90 and 93 are localized within the phenol binding site of human UDP-glucuronosyltransferase 1A10 as determined by photoaffinity labeling, mass spectrometry, and site-directed mutagenesis. *Biochemistry*, **2006**, 45, 2322-32	3.2	35
35	Phe90 is a crucial amino acid within the estrogen binding site of the human UDP-glucuronosyltransferase 1A10. *FASEB Journal*, **2006**, 20, A470	0.9	
34	Transcriptional Regulation of UDP-Glucuronosyltransferases **2005**, 133-171		
33	A historical overview of the heterologous expression of mammalian UDP-glucuronosyltransferase isoforms over the past twenty years. *Current Drug Metabolism*, **2005**, 6, 141-60	3.5	49
32	Human UDP-glucuronosyltransferase 1A5: identification, expression, and activity. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 315, 1143-9	4.7	56
31	Lithocholic acid decreases expression of UGT2B7 in Caco-2 cells: a potential role for a negative farnesoid X receptor response element. *Drug Metabolism and Disposition*, **2005**, 33, 937-46	4	49
30	Structure of UDP-glucuronosyltransferases in membranes. *Methods in Enzymology*, **2005**, 400, 116-47	1.7	38
29	Glucuronidation of Fatty Acids and Prostaglandins by Human UDP-Glucuronosyltransferases **2005**, 109-132		
28	Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression. *Drug Metabolism and Disposition*, **2004**, 32, 340-7	4	135
27	Glucuronidation of oxidized fatty acids and prostaglandins B1 and E2 by human hepatic and recombinant UDP-glucuronosyltransferases. *Journal of Lipid Research*, **2004**, 45, 1694-703	6.3	39
26	Orphan nuclear receptor-mediated xenobiotic regulation in drug metabolism. *Drug Discovery Today*, **2004**, 9, 442-9	8.8	103
25	Carboxyl nonsteroidal anti-inflammatory drugs are efficiently glucuronidated by microsomes of the human gastrointestinal tract. *Biochimica Et Biophysica Acta - General Subjects*, **2004**, 1675, 120-9	4	17
24	Glucosidation of hyodeoxycholic acid by UDP-glucuronosyltransferase 2B7. *Biochemical Pharmacology*, **2003**, 65, 417-21	6	36

23	Human gastrointestinal sulfotransferases: identification and distribution. *Toxicology and Applied Pharmacology*, **2003**, 187, 186-97	4.6	65
22	Glucuronidation of catechols by human hepatic, gastric, and intestinal microsomal UDP-glucuronosyltransferases (UGT) and recombinant UGT1A6, UGT1A9, and UGT2B7. *Archives of Biochemistry and Biophysics*, **2003**, 411, 251-61	4.1	36
21	Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 4150-5	11.5	309
20	Glucuronidation of the dietary fatty acids, phytanic acid and docosahexaenoic acid, by human UDP-glucuronosyltransferases. *Drug Metabolism and Disposition*, **2002**, 30, 531-3	4	28
19	Critical role of diacylglycerol- and phospholipid-regulated protein kinase C epsilon in induction of low-density lipoprotein receptor transcription in response to depletion of cholesterol. *Molecular and Cellular Biology*, **2002**, 22, 3783-93	4.8	30
18	Photoaffinity labeling of human retinoid X receptor beta (RXRbeta) with 9-cis-retinoic acid: identification of phytanic acid, docosahexaenoic acid, and lithocholic acid as ligands for RXRbeta. *Biochemistry*, **2002**, 41, 4883-90	3.2	30
17	Nuclear UDP-glucuronosyltransferases: identification of UGT2B7 and UGT1A6 in human liver nuclear membranes. *Archives of Biochemistry and Biophysics*, **2002**, 399, 37-48	4.1	27
16	Interindividual variation and organ-specific patterns of glutathione S-transferase alpha, mu, and pi expression in gastrointestinal tract mucosa of normal individuals. *Archives of Biochemistry and Biophysics*, **2002**, 403, 270-6	4.1	71
15	Application of photoaffinity labeling with [(3)H] all trans- and 9-cis-retinoic acids for characterization of cellular retinoic acid--binding proteins I and II. *Protein Science*, **2001**, 10, 200-11	6.3	4
14	Glucuronidation of linoleic acid diols by human microsomal and recombinant UDP-glucuronosyltransferases: identification of UGT2B7 as the major isoform involved. *Archives of Biochemistry and Biophysics*, **2001**, 389, 176-86	4.1	19
13	4-hydroxyretinoic acid, a novel substrate for human liver microsomal UDP-glucuronosyltransferase(s) and recombinant UGT2B7. *Journal of Biological Chemistry*, **2000**, 275, 6908-14	5.4	91
12	Direct interaction of all-trans-retinoic acid with protein kinase C (PKC). Implications for PKC signaling and cancer therapy. *Journal of Biological Chemistry*, **2000**, 275, 22324-30	5.4	84
11	Linoleic acid diols are novel substrates for human UDP-glucuronosyltransferases. *Archives of Biochemistry and Biophysics*, **2000**, 380, 294-302	4.1	27
10	Carboxyl residues in the active site of human phenol sulfotransferase (SULT1A1). *Biochemistry*, **2000**, 39, 16000-7	3.2	26
9	Direct photoaffinity labeling of cellular retinoic acid-binding protein I (CRABP-I) with all-trans-retinoic acid: identification of amino acids in the ligand binding site. *Biochemistry*, **2000**, 39, 12568-74	3.2	14
8	Human and Rat Liver UDP-Glucuronosyltransferases Are Targets of Ketoprofen Acylglucuronide. *Molecular Pharmacology*, **1999**, 56, 226-234	4.3	48
7	Photoaffinity labeling probe for the substrate binding site of human phenol sulfotransferase (SULT1A1): 7-azido-4-methylcoumarin. *Protein Science*, **1999**, 8, 2151-7	6.3	33
6	Differential glucuronidation of bile acids, androgens and estrogens by human UGT1A3 and 2B7. *Journal of Steroid Biochemistry and Molecular Biology*, **1999**, 70, 101-8	5.1	120

5	Photoaffinity labeling of the aglycon binding site of the recombinant human liver UDP-glucuronosyltransferase UGT1A6 with 7-azido-4-methylcoumarin. *Archives of Biochemistry and Biophysics*, **1999**, 368, 75-84	4.1	12
4	Structural and functional studies of UDP-glucuronosyltransferases. *Drug Metabolism Reviews*, **1999**, 31, 817-99	7	417
3	A functional role for histidyl residues of the UDP-glucuronic acid carrier in rat liver endoplasmic reticulum membranes. *Biochemistry*, **1998**, 37, 258-63	3.2	12
2	Cloning and expression of human UDP-glucuronosyltransferase (UGT) 1A8. *Archives of Biochemistry and Biophysics*, **1998**, 356, 301-5	4.1	100
1	UDP-glucuronosyltransferases in human intestinal mucosa. *Lipids and Lipid Metabolism*, **1998**, 1394, 199-208		83